thebench.bio #1 Ecosystem for the Bio-Tech Industry

Industry Daily Summary

Industry Daily Summary: What Happened on November 12, 2026

October biopharma layoffs rise, but 2026 cuts remain below 2025

More workers were affected by October cuts than a year earlier. Third-quarter job postings also increased, while Lakefront ended a drug program.

  • Updated
  • Read from 10 articles, 8 publications
  • P +2

Today in brief

Fifteen biopharma companies made or planned layoffs in October, with affected workers up 43% from October 2025.1 By October, 99 companies had cut or planned cuts affecting 19,538 people, compared with 200 companies and 43,242 people in all of 2025.1

Lakefront Biotherapeutics stopped developing GLPG3667 after mixed Phase 2 results in dermatomyositis and lupus.2 BioSpace counted more third-quarter job postings and fewer layoffs year over year. Bristol Myers Squibb also put research and development under its chief medical officer.3456

October layoffs rose, while 2026 cuts remain below last year's

In October, 15 biotech and pharmaceutical companies made or planned layoffs. It was the first month in 2026 when both the number of employers and workers affected exceeded October 2025.1 Three more employers reported or anticipated cuts than a year earlier, and the affected-worker total rose 43%.1

Six companies planned to cut at least half their workforces.1 Artiva Biotherapeutics plans to cut 94% of its workforce, affecting 131 employees starting December 31, and is weighing a transaction, licensing or dissolution.1 Artiva is ending AlloNK development after two patient deaths and concerns about the duration of clinical responses.1

Caribou Biosciences plans to dismiss 87 employees effective December 7 and stop advancing its clinical-stage pipeline.1 The company said a financing freeze in the CAR T field prompted the cuts and its review of strategic options.1 LENZ Therapeutics plans to cut about 75% of its workforce, leaving roughly 40 full-time employees. The company said its chief executive will leave December 1.1

GSK plans to eliminate more than 1,200 roles in Belgium under a three-year, $2.5 billion global restructuring.1 The company said it will redirect resources toward late-stage programs and research and development.1 BioSpace counted cuts affecting 43,242 employees at 200 biopharmas in 2025. Through October 2026, its tally was 19,538 people at 99 companies.1

Lakefront ends GLPG3667 after mixed Phase 2 results

Lakefront disclosed on November 11 that it had discontinued the oral TYK2 inhibitor after reviewing its competitive position and discussing the program with potential partners.2 In the Phase 2 dermatomyositis study, patients on the drug scored better than those on placebo on a composite measure after 24 weeks.2 The result met the trial's prespecified 10% significance threshold, but not the conventional 5% threshold.2 The drug did not meet the primary endpoint in a lupus study.2

Lakefront said the decision followed a review of its portfolio priorities, the competitive position and market opportunity. It did not expect a material cost.2 The company said it remains open to licensing inquiries for discontinued programs but has not specified the future of GLPG3667's rights.2 Lakefront expects its Phase 1b autoimmune program gamgertamig to enter registrational studies in 2027.2

Also worth knowing

  • BioSpace counted 31% more live job postings on its site in the third quarter than a year earlier. Layoffs affected 2,568 employees at 27 companies, down 90% by headcount and 56% by company count year over year.3

  • Bristol Myers Squibb is combining its research and development department under Chief Medical Officer Cristian Massacesi. Research chief Robert Plenge is set to leave in March.456

  • Sean Keveney said he would leave his post as FDA chief counsel. Novo Nordisk named Galderma CFO Luigi La Corte to succeed Karsten Munk Knudsen, who is leaving after 27 years at the company.7

  • P

    Europa Biosite will enter the Czech Republic through its pending purchase of MEDISTA, a Czech distributor of diagnostics and laboratory technology. The deal is subject to customary regulatory approvals.89

  • P

    Lilly's oral GLP-1 obesity treatment reached China before Novo's.10

Also published